Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of RO5545965 in Schizophrenia
NCT02019329Phase 1Completed
- Sponsor
- Roche
- Start
- Jan 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in schizophrenia comparing Placebo + risperidone with RO5545965 + risperidone (2 arms). Primary endpoints: Incidence of adverse events up to 10 weeks and Health of the patients up to 10 weeks. Started Jan 2014; status: completed.
02
Drugs
RO5545965
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02019329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02019329.